DimiCare Biotech

Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, Fundamental researchers, and Financial experts, assuring solid growth not only in the scientific but also in the business field. Currently, our projects have been awarded by the Innovation program from Labex SIGNALIFE (Young Entrepreneur Program) and we are currently searching for new funding to support the continuity of the project. If you are interested in our research and want to contact us for collaboration or just to talk, do not hesitate to contact me through any of the options available in my profile.